Autonomix Medical Secures New European Patent For Precision Cardiac Neuromodulation

With over 80 issued patents and 39 pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation

Newly granted patent further strengthens the Company's strategic position in a multi-billion-dollar market opportunity, unlocking potential across cardiovascular, renal, and other high-burden diseases

THE WOODLANDS, TX, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the European Patent Office (EPO) has granted Patent No. EP4230133 (the ‘133 patent), titled, "Controlled and Precise Treatment of Cardiac Tissues." The newly granted ‘133 patent covers systems, devices, and methods that sense autonomic/cardiac signals, map targets, and then deliver therapy with closed-loop feedback to precisely treat cardiac tissues by performing feedback-driven neuromodulation, denervation, and/or ablation of tissues.